Cart
sales@molnova.com
Alendronic Acid
CAS No. 66376-36-1
Alendronic Acid( alendronate )
Catalog No. M20828 CAS No. 66376-36-1
Alendronic acid is a nonhormonal medication used for osteoporosis osteogenesis imperfecta and several other bone diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 37 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 75 | In Stock |
|
| 1G | 105 | In Stock |
|
Biological Information
-
Product NameAlendronic Acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlendronic acid is a nonhormonal medication used for osteoporosis osteogenesis imperfecta and several other bone diseases.
-
DescriptionAlendronic acid is a nonhormonal medication used for osteoporosis osteogenesis imperfecta and several other bone diseases.
-
In Vitro——
-
In Vivo——
-
Synonymsalendronate
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number66376-36-1
-
Formula Weight249.1
-
Molecular FormulaC4H13NO7P2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 3.7 mg/mL (14.85 mM)
-
SMILESNCCCC(O)(P(=O)(O)O)P(=O)(O)O
-
Chemical Name(4-Amino-1-hydroxybutylidene)diphosphonic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Martín Siguero A áreas Del águila VL Franco Sereno M T et al. Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.[J]. Farm Hosp 2015 39(6):350-354.
molnova catalog
related products
-
S961 TFA
S961 TFA is A high affinity insulin receptor (IR) antagonist with IC50 for hir-a, hir-b and human insulin-like growth factor I receptor (higf-ir) at 0.048, 0.027 and 630 nM, respectively.
-
Ximoprofen
Ximoprofen is a novel anti-inflammatory compound for the study of spondylitis.
-
Arecaidine HydrobroM...
Arecaidine hydrobromide, a pyridine alkaloid, is a potent GABA uptake inhibitor. Arecaidine hydrobromide is a substrate of H+-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits L-proline uptake.
